An Investigator-initiated, Multicenter, Phase IV, Open-label Study to Evaluate the Biological Basis for Disease Progression in Relapsing-remitting Multiple Sclerosis Patients Treated in Routine Practice With Gilenya for 2 Years
Phase of Trial: Phase IV
Latest Information Update: 12 Nov 2018
Price : $35 *
At a glance
- Drugs Fingolimod (Primary)
- Indications Multiple sclerosis
- Focus Biomarker; Therapeutic Use
- Acronyms IGLOO
- 30 Oct 2018 Status changed from active, no longer recruiting to completed.
- 31 Aug 2018 Biomarkers information updated
- 02 Oct 2017 Planned number of patients changed from 400 to 100.